Newron Pharmaceuticals S.p.A. (OTCMKTS:NWPHF) Sees Significant Decrease in Short Interest

Newron Pharmaceuticals S.p.A. (OTCMKTS:NWPHF) was the target of a large decline in short interest during the month of January. As of January 15th, there was short interest totaling 70,538 shares, a decline of 23.0% from the December 31st total of 91,573 shares. Based on an average daily volume of 0 shares, the short-interest ratio is presently ∞ days. Approximately 0.4% of the company’s stock are short sold. Approximately 0.4% of the company’s stock are short sold. Based on an average daily volume of 0 shares, the short-interest ratio is presently ∞ days.

Newron Pharmaceuticals Price Performance

Newron Pharmaceuticals stock opened at $9.36 on Friday. Newron Pharmaceuticals has a one year low of $9.10 and a one year high of $12.00. The company’s fifty day moving average price is $9.36 and its two-hundred day moving average price is $9.36.

About Newron Pharmaceuticals

Newron Pharmaceuticals SpA is a clinical-stage biopharmaceutical company headquartered in Bresso, Italy, dedicated to developing novel therapies for central nervous system (CNS) disorders. The company’s research and development efforts focus on small-molecule compounds designed to address unmet medical needs in neurology and psychiatry.

Newron’s lead product, safinamide, is marketed under the brand name Xadago as an adjunctive therapy for patients with mid- to late-stage Parkinson’s disease.